Cargando…

T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape

Bispecific chimeric antigen receptor T-cell (CAR-T) therapies have shown promising results in clinical trials for advanced B-cell malignancies. However, it is challenging to broaden the success of bispecific CAR-T therapies to treat refractory/relapse (r/r) T-cell leukemia/lymphoma because targeting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dai, Zhenyu, Mu, Wei, Zhao, Ya, Cheng, Jiali, Lin, Haolong, Ouyang, Kedong, Jia, Xiangyin, Liu, Jianwei, Wei, Qiaoe, Wang, Meng, Liu, Chaohong, Tan, Taochao, Zhou, Jianfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948246/ https://www.ncbi.nlm.nih.gov/pubmed/35332132 http://dx.doi.org/10.1038/s41392-022-00898-z

Ejemplares similares

The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains
por: Dai, Zhenyu, et al.
Publicado: (2021)

Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function
por: Leung, Isabel, et al.
Publicado: (2022)

CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluated
por: Kim, Hyori, et al.
Publicado: (2023)

Fully human CD19-specific chimeric antigen receptors for T-cell therapy
por: Sommermeyer, Daniel, et al.
Publicado: (2017)

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
por: Lam, Norris, et al.
Publicado: (2020)

A bispecific chimeric antigen receptor molecule enhances T cell activation through dual immunological synapse formation and offsets antigen escape in glioblastoma
por: Hegde, Meenakshi, et al.
Publicado: (2015)

Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy
por: Liang, Zuyu, et al.
Publicado: (2020)

Author Correction: Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
por: Lam, Norris, et al.
Publicado: (2020)

A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
por: Wang, Yiyun, et al.
Publicado: (2020)

Minimizing leukemia escape: implementing a dual anti-CD20- and CD19-scFv-based chimeric antigen receptor (CAR)
por: Schneider, Dina, et al.
Publicado: (2015)

Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity
por: Wang, Zhenzhen, et al.
Publicado: (2023)

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
por: Grada, Zakaria, et al.
Publicado: (2013)

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
por: Alsajjan, Roa, et al.
Publicado: (2023)

The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
por: Muller, Yannick D., et al.
Publicado: (2021)

Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma
por: Tseng, Hsiang-chi, et al.
Publicado: (2020)

Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells
por: SAKAI, Osamu, et al.
Publicado: (2021)

Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
por: Cronk, Robert J., et al.
Publicado: (2020)

Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia
por: Ma, Gina, et al.
Publicado: (2018)

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
por: Qin, Haiying, et al.
Publicado: (2018)

Monitoring anti‐CD19 chimeric antigen receptor T cell population by flow cytometry and its consistency with digital droplet polymerase chain reaction
por: Cheng, Jiali, et al.
Publicado: (2022)

CD8(+) chimeric antigen receptor T cells manufactured in absence of CD4(+) cells exhibit hypofunctional phenotype
por: Lee, Sang Yun, et al.
Publicado: (2023)

Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice
por: Hu, Xiaomeng, et al.
Publicado: (2023)

Doxycycline Inducible Chimeric Antigen Receptor T Cells Targeting CD147 for Hepatocellular Carcinoma Therapy
por: Zhang, Ren-Yu, et al.
Publicado: (2019)

A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors
por: De Oliveira, Satiro N, et al.
Publicado: (2013)

Post-CD19 Chimeric Antigen Receptor T-Cell Therapy Cytomegalovirus Retinitis
por: Bin dokhi, Haifa, et al.
Publicado: (2022)

CD38 as a pan-hematologic target for chimeric antigen receptor T cells
por: Glisovic-Aplenc, Tina, et al.
Publicado: (2023)

Efficient chimeric antigen receptor targeting of a central epitope of CD22
por: Casey, Nicholas Paul, et al.
Publicado: (2023)

Treatment of leukemia antigen-loss relapses occurring after CD19-targeted immunotherapies by combination of anti-CD123 and anti-CD19 chimeric antigen receptor T cells
por: Ruella, Marco, et al.
Publicado: (2015)

Design and Production An Effective Bispecific Tandem Chimeric Antigen Receptor on T Cells against CD123 and Folate Receptor ß towards B-Acute Myeloid Leukaemia Blasts
por: Ghamari, Ali, et al.
Publicado: (2021)

Molecular Characterization of a Fully Human Chimeric T-Cell Antigen Receptor for Tumor-Associated Antigen EpCAM
por: Shirasu, Naoto, et al.
Publicado: (2012)

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients
por: Wang, D., et al.
Publicado: (2020)

Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma
por: Sang, Wei, et al.
Publicado: (2022)

Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells
por: Strohl, William R., et al.
Publicado: (2019)

Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job
por: Schwerdtfeger, Melanie, et al.
Publicado: (2021)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers
por: Becker, Scott A., et al.
Publicado: (2023)

Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers
por: Anderson, John, et al.
Publicado: (2023)

Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma
por: Wang, Yitian, et al.
Publicado: (2019)

Apoptosis of CD19(+) chimeric antigen receptor T cells after treatment with chemotherapeutic agents
por: Yi, Wenfang, et al.
Publicado: (2018)

Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
por: Chen, Kevin H., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ccum1mv2l557g591m6n1eavf8a